ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ALX Oncology (Nasdaq: ALXO) will present updated Phase 2 ASPEN-06 data at the SITC 40th Annual Meeting (Nov 5–9, 2025) in National Harbor, MD. The poster reports that CD47 expression is a predictive biomarker for response to evorpacept in previously treated HER2-positive gastric and gastroesophageal junction cancer.
ASPEN-06 tested evorpacept combined with trastuzumab, ramucirumab, and paclitaxel. Poster details: Title "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," First Author Zev A. Wainberg, M.D., Abstract 496, presented Saturday, November 8, 2025, 10:00 a.m.–6:35 p.m. ET in Poster Hall (Exhibit Halls AB).
ALX Oncology (Nasdaq: ALXO) presenterà dati aggiornati di Fase 2 ASPEN-06 al SITC 40th Annual Meeting (5–9 novembre 2025) a National Harbor, MD. Il poster riporta che l'espressione di CD47 è un biomarker predittivo di risposta a evorpacept in cancro gastrico HER2-positivo e al giunto gastroesofageo precedentemente trattato.
ASPEN-06 ha testato evorpacept in combinazione con trastuzumab, ramucirumab e paclitaxel. Dettagli del poster: Titolo "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," Primo Autore Zev A. Wainberg, M.D., Abstract 496, presentato sabato, 8 novembre 2025, ore 10:00–18:35 ET nel Poster Hall (Exhibit Halls AB).
ALX Oncology (Nasdaq: ALXO) presentará datos actualizados de Fase 2 ASPEN-06 en la 40ª Reunión Anual SITC (del 5 al 9 de noviembre de 2025) en National Harbor, MD. El póster informa que la expresión de CD47 es un biomarcador predictivo de respuesta a evorpacept en cáncer gástrico y de unión gastroesofágica HER2-positivo previamente tratado.
ASPEN-06 probó evorpacept en combinación con trastuzumab, ramucirumab y paclitaxel. Detalles del póster: Título "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," Autor Principal Zev A. Wainberg, M.D., Abstract 496, presentado el sábado, 8 de noviembre de 2025, de 10:00 a.m. a 6:35 p.m. ET en Poster Hall (Exhibit Halls AB).
ALX Oncology (나스닥: ALXO)는 SITC 40th Annual Meeting에서 업데이트된 2상 ASPEN-06 데이터를 National Harbor, MD에서 2025년 11월 5–9일에 발표할 예정입니다. 포스터에 따르면 CD47 발현은 이전에 치료 받은 HER2-양성 위암 및 위식인접부 암에서 evorpacept에 대한 반응의 예측 바이오마커입니다.
ASPEN-06은 evorpacept를 트라스투주맙, 라마큐리무밥 및 파클리탁셀과의 조합으로 테스트했습니다. 포스터 세부 정보: 제목 "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," 제1 저자 Zev A. Wainberg, M.D., Abstract 496, 2025년 11월 8일 토요일, 현지 시간 10:00 a.m.–6:35 p.m. ET, 포스터 홀(Exhibit Halls AB)에서 발표.
ALX Oncology (Nasdaq: ALXO) présentera des données actualisées de la Phase 2 ASPEN-06 à la 40e réunion annuelle SITC (du 5 au 9 novembre 2025) à National Harbor, MD. Le poster indique que l’expression de CD47 est un biomarqueur prédictif de la réponse à evorpacept chez des patients préalablement traités pour un cancer gastrique HER2-positif et junction gastro-œsophagienne.
ASPEN-06 a testé evorpacept en combinaison avec trastuzumab, ramucirumab et paclitaxel. Détails du poster: Titre "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," Premier auteur Zev A. Wainberg, M.D., Résumé 496, présenté le samedi, 8 novembre 2025, de 10h00 à 18h35 ET dans le Poster Hall (Exhibit Halls AB).
ALX Oncology (Nasdaq: ALXO) wird aktualisierte Phase-2-Daten des ASPEN-06 auf der SITC 40th Annual Meeting (5.–9. November 2025) in National Harbor, MD präsentieren. Das Poster berichtet, dass CD47-Expression ein prädiktiver Biomarker für die Reaktion auf evorpacept bei zuvor behandeltem HER2-positivem Magen- und gastroösophagealen Junction-Krebs ist.
ASPEN-06 testete evorpacept in Kombination mit Trastuzumab, Ramucirumab und Paclitaxel. Poster-Details: Titel "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," Erstautor Zev A. Wainberg, M.D., Abstract 496, präsentiert am Samstag, 8. November 2025, von 10:00 bis 18:35 Uhr ET im Poster Hall (Exhibit Halls AB).
ALX Oncology (المدرجة في ناسداك: ALXO) ستعرض بيانات المرحلة 2 المحدثة ASPEN-06 في اجتماع SITC السنوي الأربعين (5–9 نوفمبر 2025) في National Harbor، MD. يشير الملصق إلى أن تعبير CD47 هو علامة بيولوجية قابلة للتنبؤ باستجابة لـ evorpacept في سرطان المعدة HER2-الإيجابي وسلسلة الفاصل المريئي القلوي المعالج سابقاً.
اختبرت ASPEN-06 evorpacept بالاشتراك مع تراستوزوماب، راموسيروماب و باكليتاكيل. تفاصيل الملصق: العنوان "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," المؤلف الأول Zev A. Wainberg، M.D.، الملخص 496، مقدم يوم السبت، 8 نوفمبر 2025، من 10:00 صباحاً إلى 6:35 مساءً بتوقيت شرق الولايات المتحدة في Poster Hall (Exhibit Halls AB).
ALX Oncology (纳斯达克: ALXO) 将在 SITC 40th Annual Meeting（2025年11月5–9日）于 National Harbor, MD 发表更新的第2阶段 ASPEN-06 数据。海报显示，CD47 表达是对 evorpacept 在先前治疗的 HER2 阳性胃癌及胃-食管连接区癌中的反应的预测生物标志物。
ASPEN-06 将 evorpacept 与 曲妥珠单抗、雷木司珠单抗 和 紫杉醇 联合使用进行了测试。海报详情：标题 "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," 第一作者 Zev A. Wainberg, M.D., 摘要 496，提交时间为星期六，2025年11月8日，东部时间上午10:00–下午6:35，在 Poster Hall（Exhibit Halls AB）展示。
- None.
- None.
- Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The Phase 2 trial evaluated evorpacept, the Company’s lead therapeutic candidate, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.
Details for the poster presentation at SITC 2025 are as follows:
Title: CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial
First Author: Zev A. Wainberg, M.D., Professor of Medicine and Co-Director of GI Oncology Program, University of California, Los Angeles
Abstract: 496
Date and Time: Saturday, November 8, 2025, 10:00 a.m. – 6:35 p.m. ET
Location: Poster Hall (Exhibit Halls AB)
About ASPEN-06
ASPEN-06 is a randomized Phase 2 (open-label)/3 (blinded), international, multi-center study, evaluating evorpacept in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with metastatic second- or third-line HER2 overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy. One hundred twenty-seven adult patients were enrolled in the Phase 2 portion of the study.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objectives of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577
FAQ
When will ALX Oncology (ALXO) present ASPEN-06 Phase 2 data at SITC 2025?
What does the ALX Oncology (ALXO) poster at SITC 2025 report about CD47 in HER2+ gastric cancer?
Which regimen was evaluated in the ASPEN-06 trial presented by ALX Oncology (ALXO)?
Who is the first author of the ALX Oncology (ALXO) SITC 2025 poster and what is the abstract number?
Where at SITC 2025 will ALX Oncology (ALXO) display the ASPEN-06 poster?
What patient population was included in ALX Oncology's (ALXO) ASPEN-06 Phase 2 trial?
